Anecortave acetate for fibrotic lesions with presence of residual peripheral activity in age-related macular degeneration.
We retrospectively examined the efficacy of a single juxtascleral anecortave acetate depot injection for the treatment of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration in 20 consecutive patients who rejected intravitreal treatment. As a second line-therapy of classic and occult fibrotic lesions with active peripheral zones, anecortave seems to be a vision conserving therapeutic option.
Aggermann
Tina
T
Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery, Vienna, Austria. tina@aggermann.at
Haas
Paulina
P
Binder
Susanne
S
D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D005260:Female; D005355:Fibrosis; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D011244:Pregnadienediols / Q000627:therapeutic use*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D011244:Pregnadienediols; C418047:anecortave acetate